Long-term outcomes of patients with unresectable benign meningioma treated with proton beam therapy. (13th April 2021)

• Record Type: Journal Article
• Authors: Sato, Hiroshige; Mizumoto, Masashi; Okumura, Toshiyuki; Sakurai, Hideyuki; Sakamoto, Noriaki; Akutsu, Hiroyoshi; Ishikawa, Eiichi; Tsuboi, Koji
• Is Part Of: Journal of radiation research. Volume 62:Number 3(2021)
• Page Start: 427
• Page End: 437
• Publication Date: 2021-04-13
• Subjects: benign meningioma -- long-term control -- proton beam -- radiotherapy; Radiology, Medical -- Periodicals; Radiobiology -- Periodicals; Radiation -- Periodicals; 616.0757
• DOI: 10.1093/jrr/rrab017
• Languages: English
• ISSNs: 0449-3060

Abstract

Abstract: This study aimed to evaluate the long-term efficacy of proton beam therapy (PBT) for unresectable benign meningiomas at the University of Tsukuba, Japan. From 1986–1998, 10 patients were treated at the Particle Radiation Medical Science Center (PRMSC) with a relative biological effectiveness (RBE) value of 1.0 using an accelerator built for physics experiments. The total dose was compensated with an X-ray in three patients. Following that, from 2002–2017, 17 patients were treated with a RBE value of 1.1 at the Proton Medical Research Center (PMRC) which was built for medical use. At the PRMSC, the total dose ranged from 50.4–66 Gy (median: 54 Gy). During the follow-up, which lasted between 3.8 and 31.6 years (median: 25.1 years), the 5-, 10-, 15-, 20- and 30-year local control rates were 100%, and the 5-, 10-, 15-, 20- and 30-year survival rates were 90, 80, 70, 70 and 36%, respectively. One patient died of brainstem radiation necrosis 5.1 years after PBT. At PMRC, the total dose ranged from 45.0–61.2 GyE, with a median of 50.4 GyE. During the follow-up, which lasted between 3 and 17 years with a median of 10.5 years, the 5-, 10- and 15-year local control rates were 94.1%, and the 5-, 10- and 15-year survival rates were 100, 100 and 88.9%, respectively. Neither malignant transformation nor secondary malignancy was observed, indicating that fractionated PBT may be effective and safely control benign unresectable meningioma even for the lifelong period of time.